NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company which develops, manufactures and markets life-saving medicines, has been granted approval by the European Agency for the Evaluation of Medicinal Products (EMEA) for its plans for phase II / III clinical trials of the inhaled version of its Alpha-1 Antitrypsin [AAT] product. AAT is used in treatment of Congenital Emphysema, caused by inborn deficiency of AAT.
